EGX100

Commercial International Bank (CIB - COMI) Here is the institutional-grade technical report translated into professional financial English: 🛑 Technical & Structural Evaluation Report: Commercial International Bank (CIB - COMI) Date: May 2026 Report Type: Urgent Update – Trend Reversal & Distribution Evaluation Current Status: Active Downside Slippage (In-Progress Free Fall) I. Executive Summary The Commercial International Bank (CIB) stock is currently undergoing a Major Institutional Distribution Phase after testing its historical peak near the 144.78 EGP level. Multi-timeframe technical indicators explicitly confirm a complete exhaustion of buying momentum alongside an aggressive expansion in selling pressure (Smart Money Outflow). We strongly recommend exercising extreme caution and temporarily neutralizing long positions, as the stock has entered an active liquidation phase targeting deeper structural supports. II. Technical & Price Action Anatomy 1. Chart Patterns & Market Structure: Triple Top Pattern: Multi-frame chart analysis reveals a clear failure by buyers to break above or sustain prices over the key historical resistance zone of on three consecutive attempts. This recurring rejection underscores a major momentum exhaustion, validating the formation of a macro Triple Top distribution pool. Trendline Break: The price has decisively broken below its primary ascending trendline (the main driver of the recent rally) with zero immediate bullish reaction. This structural shift officially transitions the stock from a consolidation phase into a vertical downward trajectory. 2. Volume Profile & Money Flow: Chaikin Money Flow (CMF) Deterioration: The CMF indicator displays a severe negative divergence, dropping deeply to (-0.47) on the 4-hour frame and deteriorating further to an extreme (-0.65) on intraday frames (45-minute). This indicates heavy institutional liquidation and aggressive distribution that completely absorbs any localized buying depth. Price-Volume Relationship: The latest bearish candles are strictly accompanied by significant volume spikes. This volume expansion during a price drop validates the presence of heavy institutional selling rather than retail panic. 3. Moving Average Ribbon Matrix: The price is currently trading below its short-term exponential and simple moving averages (20 & 50 periods), which have now flipped into static and dynamic resistance zones capping any upside near . The current downside velocity has pushed the price below the slower 100 and 200-period averages on intraday charts, stripping the stock of its immediate cushion levels. III. Downside Targets Based on structural extension measurements and historical liquidity gaps, the downside targets are projected sequentially as follows: 🎯 First Target (130.00 EGP): Represents the closest psychological support level and the 50-day moving average (DMA) low on the daily frame. Given the current selling velocity, this level is highly vulnerable to an immediate break. 🎯 Second Target (117.00 EGP): A critical structural station representing the Major Accumulation Zone established during March and April. Institutional buying interest is expected to re-emerge here, potentially triggering a technical relief bounce. 🎯 Third Target (108.00 EGP): This station marks the initial breakout point of the macro rally and serves as a major structural retest. It also aligns with the mandatory filling of the large price gap created at the beginning of the year. 🛑 Strategic Ultimate Target (95.00 EGP): Should the selling pressure intensify and decisively break the 108.00 EGP floor, the stock will inevitably drift toward its "concrete baseline"—the core accumulation base that sustained the stock throughout 2023. IV. Recommendation & Operational Strategy For Day Traders / Short-Term Investors: Implement a strict Capital Preservation strategy. Any temporary intraday relief rallies (Technical Bounces) lacking massive volume confirmation must be treated as a Bull Trap designed to distribute residual blocks. These should be utilized to trim existing positions rather than initiating new buy orders. For Medium to Long-Term Investors: Refrain entirely from "catching a falling knife." It is highly advised to stand aside and closely monitor the price action at the first major structural cushion around , tracking the volume profile and money flow to ensure a verified institutional re-accumulation process begins before allocating capital. Disclaimer: This report represents a purely technical and structural assessment of price behavior and capital flow based on available chart data. It does not constitute a direct solicitation or recommendation to buy or sell. The final investment decision and the responsibility for risk management rest entirely with the portfolio manager or individual investor.

LUTS - Target 1.08 Entry at 0.57 LE. Target set at 1.08 LE. Risk note: Manage position size accordingly.

ECAP isn't getting enough love, yet - While the whole market is trending with no questions asked, ECAP is still hanging where a great R:R exists. - But, it in fact went up a lot from high 18 to high 23.

Let's talk about OBRI - A beaten down ticker is not that attractive until the market says so. - it is still hanging around a good entry area. - the upside short term may be limited to 0.50 to 1 pound of gain (aka 7). However OBRI has a history of being highly volatile, do we get that during the coming months?

BICO risen from 27 to 41 in 5 months Rapid change with almost certain assistance from its parent company What happened during the past period is like a miracle. The company transformed after the first quarter results showed huge losses and embezzlement charges that resulted in restructuring. After the distribution of closed dividends per share was suspended at 0.75 until liquidity was available, and liquidity was available quickly. I believe that financing was provided by the parent company in exchange for an export share and benefiting from the currency difference after the delay in the Medicine Authority’s decision to move the exchange rate. The pending dividends were issued to shareholders and we await the second-quarter results, which look promising I expect the stock to rise to 30 pounds during the month of 8, and the trend is towards 40 in January 2025.

PRDC is relentless - Consolidation after an impulsive move with a resistance around 3.08 - Breakout from this level can send it to 3.20 - 3.30 (3.40 or higher if the market keeps its momentum) - find a good entry and set a stoploss with a good R:R. -Size only to your comfort level because its all mere probability.

CIRA is waiting for a bullish market - Probably the best looking chart at the moment in the market. - market needs to be bullish for this trade to work. - its hanging now around a good R:R. - We have a gap on the monthly around the 16.40. Once we break the 14 area, we may get an impulsive move towards the gap.

Egyptian Drug Authority and Pharmaceutical Companies Ebeco Company is one of the leading pharmaceutical companies in Egypt, with a long history of manufacturing and exporting medicines. Over the past two years, the company has benefited from therapeutic supply contracts to African countries through the United Nations and the African Union, which has led to significant growth in its revenues and profits. Negative Impacts: However, the company has faced some challenges in the Egyptian market over the past seven months due to the implementation of maximum price caps for medicines by the Egyptian Drug Authority. This decision has particularly affected Ebeco, as most of its profitable medicines are antibiotics and cough syrups, which are categories of medicines that have been included in the price cap. Positive Impacts: Despite these challenges, Ebeco has been able to compensate for some of its losses by expanding its operations into Central African markets through international export companies. Short-Term Outlook: In the short term, Ebeco's share price is expected to move in a trading range between 32 and 48 Egyptian pounds. This is due to investors waiting for the Egyptian Drug Authority's approval of requests from pharmaceutical companies to raise their prices. Future Scenarios: In case of approval to raise prices: Share prices of all pharmaceutical companies are expected to rise significantly, in line with the percentage allowed for price increases. This will lead to an improvement in Ebeco's financial performance and attract more investors to the stock. In case of rejection by the Egyptian Drug Authority of requests to raise prices: The scenario of a decline in the share price and a continued trading range is likely to continue until a new development occurs. The company may face further challenges in the Egyptian market, which could negatively impact its financial performance.

Is The Market Ready to Bounce?- EGX100 is down around 27% from its high. - Today it hit a very important level, the 200 day MA which was tested before on March 2023, and also if we measure the fib level, we find that it retraced to a 50% level. - This also occurs while EGX30 hitting its 200 day MA as well. - Now we can never know for sure if this bottom or not, but we can be prepared for both scenarios. - Resistance overhead @ 8500 if this can be breached, the way is clear towards the 9000 level, and this a very critical level, as anywhere between 8500/9000 the sellers may show up again and try to push the market down. - If buyers manage to break the 9000 level, the probability that this is a bottom is high, with only the level between 9300-9700 will be left to confirm the continuation of the bull trend. - Pls note that currently the market is considered on a downtrend with 20/50/100 MA all pointing down. - Not a good advice to reenter those tickers that became so cheap, look for the ones that were holding their levels as those are the ones with higher strength comparing to the market. - It's always better and safer to wait until the market confirms the bull trend before buying.

EGX100 RISK OFF?- Market keeps rejecting 10800 level. and sellers seem to be taking control. - A lot of stocks already into bearish setups. - Noone can ever predict the price accurately all the time so Im going to keep it simple. * Bellow 9800 market is a risk off. with a handful of tickers can hold their levels. * wait for bullish reversal confirmation before entering any trades. -Remember: the market will be here tomorrow, no need to rush into trades.

Can OIH revisit its ATH?- Finally after the market shook off all the prophets of doom who were calling for a market correction the bullish trend is continuing its course. - OIH is highly liquid stock but the chart seems to be setting for a revisit of the ATH. - Entry area is the current range. - There is a good R:R so no need to have a tight stoploss.

Quick Trade on TALM - I am buying above 7.20 - chart is a bit overextended on the monthly, so I am not expecting a larger move, but I am still considering it. - I see potential for 7.70s/8/ 8.60 (maybe). - Let's bank.

Watch out for NEDA - I see higher potential if NEDA above 3.20 - Tight stop loss is not a good idea. - I wished volume was better but sometimes bulls dont need volume to push the price higher.

Steady Grind on AMOC - My entry area is marked in green - Trendline resistance @ 13.50 area - Breakout of this trendline can send it to 14.80 area. - Watch out 'cause AMOC likes to do liquidity grab, so give it space to move.

INEG high probability trade Its in a buying area around 0.190s/0.200 high probability for an impulsive move

TAQA is preparing for a move make your own decision. widen your risk as it has volatility and get fearful at 19 but leave runners.

ZMID wants to breakout !!?- probably still has a daily 5% ceiling. - It may consolidate in the channel. -Good entry is probably around 7.40-7.80 - Make your own decision, size accordingly and manage risk.

ABUK is bull flagging High probability trade on ABUK with potential target at 107 and 118. Probability 70%

Good setup on RMDA It has a probability of a good uptrend imo. the trade requires good risk management and patience.

EGX Weekly Analysis - EGX30 came near the 60% Fib level and it was due to a pullback. - It cant stay overbought for too long and a healthy pullback was necessary. - In my opinion, it can stay in a range for a couple of weeks and its a good opportunity to add more shares to winning trades. - In case the market decides to pullback more than the range. stop losses for each trades should be monitored. and sell losers.

Bull flag continuation ESRS is likely continuing its bullflag with fib levels as potential targets.

Bulls are back for EGAL?- good chance that there may be a continuation for EGAL to the upside. - Volume has decreased during consolidation, which is my only con for this trade. but it may pick up during the move. -Make your decision, size accordingly, and manage risk.

Potential trade on ISMQ stuck in a range for couple of months. already its in a good area to start adding shares imo.